demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
anticoagulant
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... COVID-PACT REMAP-CAP, ACTIV-4a, ATTACC ...
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ...

10 studies excluded by filtering options 0

5071 Tang, 2020 1133not a RCThigh risk of bias
5355 Paranjpe, 2020 1134not a RCThigh risk of bias
5679 ATTACC (Houston), 0 010selection pending
5777 Bousquet, 2020 1130not a RCTrisk of bias not avaialble
5777 Bousquet, 2020 1130not a RCTrisk of bias not avaialble
5845 ACTIV-4a (heparin), 0 010selection pending
5889 REMAP-CAP Anticoagulation, 0 010selection pending
5895 X-COVID-19, 2021 010selection pending
6283 Lynn, 2020 0130selection pending
10523 FREEDOM COVID, 2023 010selection pending